Timothy Benke
Concepts (558)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 40 | 2026 | 137 | 8.150 |
Why?
| | Epileptic Syndromes | 37 | 2026 | 98 | 7.470 |
Why?
| | Rett Syndrome | 31 | 2026 | 44 | 7.360 |
Why?
| | Seizures | 23 | 2026 | 489 | 4.340 |
Why?
| | Epilepsy | 14 | 2025 | 397 | 2.660 |
Why?
| | Methyl-CpG-Binding Protein 2 | 11 | 2026 | 24 | 2.640 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 16 | 2026 | 233 | 2.340 |
Why?
| | Receptors, AMPA | 14 | 2024 | 147 | 2.120 |
Why?
| | Hippocampus | 23 | 2025 | 986 | 1.940 |
Why?
| | Long-Term Synaptic Depression | 4 | 2025 | 49 | 1.660 |
Why?
| | Receptors, Metabotropic Glutamate | 3 | 2025 | 37 | 1.640 |
Why?
| | Long-Term Potentiation | 10 | 2024 | 206 | 1.620 |
Why?
| | Vision Disorders | 9 | 2025 | 178 | 1.550 |
Why?
| | Severity of Illness Index | 14 | 2026 | 2910 | 1.300 |
Why?
| | Clinical Trials as Topic | 5 | 2024 | 1062 | 1.220 |
Why?
| | Movement Disorders | 5 | 2023 | 68 | 1.180 |
Why?
| | Synapses | 14 | 2024 | 447 | 1.170 |
Why?
| | Psychometrics | 12 | 2025 | 708 | 1.110 |
Why?
| | Calcium Channels, L-Type | 4 | 2025 | 117 | 1.100 |
Why?
| | Excitatory Postsynaptic Potentials | 12 | 2024 | 119 | 1.090 |
Why?
| | Neurodevelopmental Disorders | 5 | 2025 | 234 | 1.030 |
Why?
| | Cognition Disorders | 10 | 2020 | 547 | 1.030 |
Why?
| | Protein Phosphatase 2 | 2 | 2025 | 41 | 0.950 |
Why?
| | Electroencephalography | 16 | 2026 | 570 | 0.910 |
Why?
| | Loss of Function Mutation | 1 | 2025 | 47 | 0.880 |
Why?
| | Genetic Testing | 3 | 2025 | 491 | 0.870 |
Why?
| | CA1 Region, Hippocampal | 4 | 2024 | 49 | 0.850 |
Why?
| | Rats, Sprague-Dawley | 14 | 2025 | 2533 | 0.840 |
Why?
| | Neuropsychological Tests | 17 | 2020 | 1136 | 0.830 |
Why?
| | Anticonvulsants | 6 | 2023 | 251 | 0.820 |
Why?
| | Internationality | 1 | 2024 | 156 | 0.810 |
Why?
| | Kainic Acid | 10 | 2024 | 33 | 0.800 |
Why?
| | Child | 57 | 2026 | 22638 | 0.790 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 15 | 0.790 |
Why?
| | Child, Preschool | 39 | 2026 | 11888 | 0.790 |
Why?
| | Brain Ischemia | 3 | 2021 | 362 | 0.770 |
Why?
| | Developmental Disabilities | 3 | 2025 | 280 | 0.770 |
Why?
| | Social Behavior | 3 | 2015 | 279 | 0.760 |
Why?
| | Autistic Disorder | 3 | 2022 | 215 | 0.730 |
Why?
| | Infarction, Posterior Cerebral Artery | 1 | 2021 | 3 | 0.690 |
Why?
| | Disease Models, Animal | 12 | 2025 | 4565 | 0.680 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 538 | 0.680 |
Why?
| | Schizophrenia | 2 | 2025 | 476 | 0.670 |
Why?
| | Caregivers | 9 | 2025 | 1079 | 0.670 |
Why?
| | Quality of Life | 11 | 2025 | 3187 | 0.670 |
Why?
| | Humans | 124 | 2026 | 145625 | 0.660 |
Why?
| | Rats | 22 | 2025 | 5574 | 0.660 |
Why?
| | Memory Disorders | 4 | 2014 | 197 | 0.660 |
Why?
| | Male | 79 | 2026 | 73014 | 0.590 |
Why?
| | Genetic Therapy | 1 | 2021 | 303 | 0.590 |
Why?
| | Communication | 5 | 2025 | 979 | 0.560 |
Why?
| | Phenotype | 14 | 2025 | 3186 | 0.560 |
Why?
| | Female | 81 | 2026 | 79080 | 0.550 |
Why?
| | Maze Learning | 3 | 2014 | 105 | 0.550 |
Why?
| | Adolescent | 43 | 2026 | 22451 | 0.530 |
Why?
| | Symptom Assessment | 1 | 2019 | 137 | 0.530 |
Why?
| | Infant | 24 | 2026 | 10093 | 0.520 |
Why?
| | Animals | 43 | 2025 | 38030 | 0.510 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 311 | 0.510 |
Why?
| | Cerebral Cortex | 7 | 2021 | 481 | 0.490 |
Why?
| | Stroke | 2 | 2021 | 1283 | 0.490 |
Why?
| | Animals, Newborn | 11 | 2024 | 887 | 0.480 |
Why?
| | Speech Disorders | 3 | 2019 | 29 | 0.470 |
Why?
| | Genomics | 1 | 2021 | 851 | 0.460 |
Why?
| | Reproducibility of Results | 13 | 2025 | 3396 | 0.460 |
Why?
| | Parents | 7 | 2025 | 1393 | 0.460 |
Why?
| | Surveys and Questionnaires | 13 | 2025 | 6050 | 0.450 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 32 | 0.450 |
Why?
| | Dementia | 6 | 2010 | 322 | 0.450 |
Why?
| | Nerve Tissue Proteins | 5 | 2026 | 594 | 0.420 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 5 | 2024 | 199 | 0.410 |
Why?
| | Young Adult | 23 | 2026 | 14240 | 0.400 |
Why?
| | Adult | 44 | 2026 | 40821 | 0.400 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 145 | 0.390 |
Why?
| | Memantine | 4 | 2026 | 18 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1790 | 0.370 |
Why?
| | Mutation | 14 | 2025 | 4082 | 0.340 |
Why?
| | Behavior, Animal | 1 | 2015 | 530 | 0.340 |
Why?
| | Nervous System Diseases | 2 | 2023 | 286 | 0.310 |
Why?
| | Glutamic Acid | 4 | 2007 | 255 | 0.310 |
Why?
| | Autism Spectrum Disorder | 3 | 2026 | 404 | 0.310 |
Why?
| | Ion Channels | 4 | 2012 | 128 | 0.310 |
Why?
| | Chromosome Duplication | 2 | 2020 | 6 | 0.310 |
Why?
| | Treatment Outcome | 14 | 2026 | 11744 | 0.300 |
Why?
| | Brain | 12 | 2026 | 2981 | 0.290 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 9 | 0.290 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 42 | 0.280 |
Why?
| | Communication Disorders | 2 | 2025 | 14 | 0.280 |
Why?
| | Evoked Potentials | 4 | 2026 | 132 | 0.270 |
Why?
| | Genetic Association Studies | 2 | 2020 | 376 | 0.270 |
Why?
| | Motor Skills | 2 | 2026 | 102 | 0.260 |
Why?
| | Space Perception | 1 | 2008 | 82 | 0.260 |
Why?
| | Risk-Taking | 2 | 2009 | 321 | 0.260 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2026 | 108 | 0.260 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 42 | 0.250 |
Why?
| | Alzheimer Disease | 2 | 2020 | 640 | 0.250 |
Why?
| | Interneurons | 2 | 2025 | 124 | 0.250 |
Why?
| | Dystonia | 1 | 2007 | 27 | 0.250 |
Why?
| | Memory, Short-Term | 2 | 2008 | 272 | 0.250 |
Why?
| | Cholinesterase Inhibitors | 2 | 2010 | 47 | 0.240 |
Why?
| | Membrane Potentials | 6 | 2023 | 278 | 0.240 |
Why?
| | Models, Neurological | 6 | 2005 | 252 | 0.240 |
Why?
| | Brain Abscess | 1 | 2006 | 10 | 0.240 |
Why?
| | Calcium | 6 | 2023 | 1181 | 0.240 |
Why?
| | Exons | 2 | 2024 | 361 | 0.240 |
Why?
| | Amnesia | 2 | 2005 | 47 | 0.230 |
Why?
| | Neurons | 7 | 2023 | 1663 | 0.230 |
Why?
| | Gain of Function Mutation | 1 | 2026 | 35 | 0.230 |
Why?
| | Indans | 1 | 2005 | 12 | 0.230 |
Why?
| | Prosencephalon | 1 | 2005 | 52 | 0.230 |
Why?
| | Pregnanolone | 2 | 2024 | 34 | 0.220 |
Why?
| | Gamma Rhythm | 1 | 2025 | 7 | 0.220 |
Why?
| | Age Factors | 5 | 2020 | 3321 | 0.220 |
Why?
| | Parkinson Disease | 6 | 2011 | 614 | 0.220 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 38 | 0.220 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.220 |
Why?
| | Amobarbital | 1 | 2005 | 2 | 0.220 |
Why?
| | Fragile X Syndrome | 1 | 2026 | 117 | 0.220 |
Why?
| | Hydrocephalus | 2 | 2024 | 114 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 11 | 2010 | 3917 | 0.220 |
Why?
| | Twins, Monozygotic | 1 | 2025 | 132 | 0.210 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 82 | 0.210 |
Why?
| | Long QT Syndrome | 2 | 2022 | 68 | 0.210 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2024 | 26 | 0.210 |
Why?
| | Delayed Diagnosis | 1 | 2025 | 102 | 0.210 |
Why?
| | Double-Blind Method | 7 | 2025 | 2064 | 0.210 |
Why?
| | Frameshift Mutation | 1 | 2024 | 31 | 0.210 |
Why?
| | Brain Diseases | 3 | 2023 | 157 | 0.210 |
Why?
| | Signal Transduction | 3 | 2024 | 5234 | 0.210 |
Why?
| | Endpoint Determination | 1 | 2024 | 84 | 0.210 |
Why?
| | Forkhead Transcription Factors | 1 | 2025 | 208 | 0.210 |
Why?
| | 5' Untranslated Regions | 1 | 2024 | 60 | 0.210 |
Why?
| | Pyramidal Cells | 4 | 2024 | 80 | 0.210 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2025 | 125 | 0.210 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 288 | 0.210 |
Why?
| | Bias | 1 | 2025 | 196 | 0.210 |
Why?
| | Tetanus Toxin | 1 | 2004 | 6 | 0.200 |
Why?
| | Mosaicism | 1 | 2024 | 67 | 0.200 |
Why?
| | Limbic Encephalitis | 1 | 2004 | 7 | 0.200 |
Why?
| | Thalamus | 2 | 2021 | 132 | 0.200 |
Why?
| | Cannabinoids | 1 | 2026 | 181 | 0.200 |
Why?
| | Piperidines | 1 | 2005 | 223 | 0.200 |
Why?
| | Disability Evaluation | 1 | 2025 | 297 | 0.200 |
Why?
| | Celiac Disease | 1 | 2007 | 285 | 0.200 |
Why?
| | Epilepsy, Temporal Lobe | 4 | 2005 | 39 | 0.200 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 147 | 0.200 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2024 | 56 | 0.200 |
Why?
| | Parvalbumins | 1 | 2023 | 26 | 0.200 |
Why?
| | Cognition | 2 | 2020 | 1286 | 0.190 |
Why?
| | Ketamine | 1 | 2025 | 141 | 0.190 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 4 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2024 | 226 | 0.190 |
Why?
| | Glycine | 1 | 2024 | 184 | 0.190 |
Why?
| | Olfactory Bulb | 1 | 2024 | 98 | 0.190 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 76 | 0.190 |
Why?
| | Ventriculostomy | 1 | 2003 | 24 | 0.190 |
Why?
| | Dendrites | 3 | 2007 | 104 | 0.190 |
Why?
| | Decision Making | 2 | 2009 | 987 | 0.190 |
Why?
| | Consensus | 1 | 2024 | 465 | 0.180 |
Why?
| | Status Epilepticus | 1 | 2023 | 71 | 0.180 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 221 | 0.180 |
Why?
| | Learning | 1 | 2007 | 446 | 0.180 |
Why?
| | Calcinosis | 1 | 2004 | 231 | 0.180 |
Why?
| | Child Behavior | 2 | 2024 | 234 | 0.180 |
Why?
| | Checklist | 1 | 2023 | 105 | 0.180 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 38 | 0.180 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 46 | 0.170 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 71 | 0.170 |
Why?
| | Phosphorylation | 3 | 2015 | 1717 | 0.170 |
Why?
| | Sleep Wake Disorders | 2 | 2024 | 314 | 0.170 |
Why?
| | Posterior Cerebral Artery | 1 | 2021 | 6 | 0.170 |
Why?
| | Ultrasonics | 1 | 2021 | 50 | 0.170 |
Why?
| | Neurologists | 1 | 2021 | 22 | 0.170 |
Why?
| | Acute Disease | 4 | 2015 | 1033 | 0.170 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 138 | 0.170 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.170 |
Why?
| | Synaptic Transmission | 4 | 2023 | 292 | 0.170 |
Why?
| | Vision, Ocular | 1 | 2021 | 47 | 0.170 |
Why?
| | Corpus Callosum | 2 | 2019 | 76 | 0.170 |
Why?
| | Visual Pathways | 1 | 2021 | 61 | 0.160 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1041 | 0.160 |
Why?
| | Subcellular Fractions | 2 | 2013 | 73 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 178 | 0.160 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 38 | 0.160 |
Why?
| | Athletic Injuries | 1 | 2007 | 574 | 0.160 |
Why?
| | Memory | 3 | 2008 | 298 | 0.160 |
Why?
| | Endoscopy | 1 | 2003 | 316 | 0.160 |
Why?
| | Middle Aged | 22 | 2026 | 36359 | 0.150 |
Why?
| | Electrophysiology | 5 | 2007 | 219 | 0.150 |
Why?
| | Follow-Up Studies | 9 | 2021 | 5397 | 0.150 |
Why?
| | Analysis of Variance | 5 | 2009 | 1293 | 0.150 |
Why?
| | Disease Progression | 3 | 2024 | 2857 | 0.150 |
Why?
| | Cyclins | 1 | 2020 | 77 | 0.150 |
Why?
| | Blotting, Western | 2 | 2015 | 1176 | 0.150 |
Why?
| | Precision Medicine | 2 | 2025 | 462 | 0.150 |
Why?
| | Mental Disorders | 2 | 2025 | 1133 | 0.150 |
Why?
| | Mutation, Missense | 4 | 2024 | 331 | 0.150 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2097 | 0.140 |
Why?
| | Action Potentials | 6 | 2023 | 498 | 0.140 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 197 | 0.140 |
Why?
| | Gene Duplication | 1 | 2019 | 67 | 0.140 |
Why?
| | Pediatrics | 1 | 2007 | 1122 | 0.140 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 28 | 0.140 |
Why?
| | Motor Activity | 2 | 2020 | 701 | 0.140 |
Why?
| | Glutamates | 3 | 2023 | 66 | 0.140 |
Why?
| | Mice | 9 | 2025 | 18266 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 39 | 0.140 |
Why?
| | Face | 1 | 2020 | 177 | 0.140 |
Why?
| | Syndrome | 3 | 2020 | 377 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.140 |
Why?
| | Judgment | 1 | 2018 | 59 | 0.130 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 6021 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2026 | 17291 | 0.130 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 66 | 0.130 |
Why?
| | Aphasia | 3 | 2004 | 24 | 0.130 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 5 | 0.130 |
Why?
| | Delphi Technique | 1 | 2019 | 347 | 0.130 |
Why?
| | Delusions | 1 | 1997 | 10 | 0.130 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 24 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 220 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2019 | 249 | 0.120 |
Why?
| | Cohort Studies | 5 | 2026 | 6045 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 992 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 578 | 0.120 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 62 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 914 | 0.120 |
Why?
| | Time | 1 | 2015 | 85 | 0.110 |
Why?
| | Physicians | 1 | 2024 | 954 | 0.110 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 17 | 0.110 |
Why?
| | Time Factors | 9 | 2009 | 7079 | 0.110 |
Why?
| | Sex Factors | 2 | 2019 | 2101 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 364 | 0.110 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 150 | 0.110 |
Why?
| | N-Methylaspartate | 2 | 1996 | 43 | 0.110 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 51 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 26 | 0.100 |
Why?
| | Lyme Disease | 1 | 1995 | 58 | 0.100 |
Why?
| | Membrane Proteins | 3 | 2010 | 1130 | 0.100 |
Why?
| | Calmodulin | 1 | 2014 | 70 | 0.100 |
Why?
| | X Chromosome Inactivation | 2 | 2025 | 25 | 0.100 |
Why?
| | Models, Molecular | 1 | 2019 | 1571 | 0.100 |
Why?
| | Aged | 14 | 2024 | 26251 | 0.100 |
Why?
| | Conotoxins | 1 | 1993 | 16 | 0.100 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 78 | 0.100 |
Why?
| | Spasm | 2 | 2023 | 21 | 0.100 |
Why?
| | Anxiety | 3 | 2022 | 1118 | 0.100 |
Why?
| | Infant, Newborn | 4 | 2024 | 6449 | 0.100 |
Why?
| | Mental Recall | 3 | 2007 | 224 | 0.100 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 36 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 173 | 0.100 |
Why?
| | Vocalization, Animal | 2 | 2024 | 28 | 0.100 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.100 |
Why?
| | Strongylida Infections | 1 | 2013 | 8 | 0.100 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 155 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2025 | 3005 | 0.090 |
Why?
| | Thiazoles | 1 | 2013 | 139 | 0.090 |
Why?
| | Pregnancy | 3 | 2013 | 7217 | 0.090 |
Why?
| | Functional Laterality | 4 | 2009 | 240 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 306 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 80 | 0.090 |
Why?
| | Down Syndrome | 2 | 2022 | 529 | 0.080 |
Why?
| | Genotype | 3 | 2022 | 1866 | 0.080 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 67 | 0.080 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 19 | 0.080 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 89 | 0.080 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 98 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 454 | 0.080 |
Why?
| | Eosinophilia | 1 | 2013 | 224 | 0.080 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 23 | 0.080 |
Why?
| | Prospective Studies | 6 | 2022 | 8087 | 0.080 |
Why?
| | Nootropic Agents | 1 | 2010 | 30 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 820 | 0.080 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 57 | 0.080 |
Why?
| | Guanylate Kinases | 1 | 2009 | 13 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 2025 | 612 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 108 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1500 | 0.070 |
Why?
| | Mathematical Concepts | 1 | 2009 | 35 | 0.070 |
Why?
| | Language Disorders | 2 | 2007 | 28 | 0.070 |
Why?
| | Pyridines | 1 | 2013 | 606 | 0.070 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 42 | 0.070 |
Why?
| | Reaction Time | 2 | 2009 | 434 | 0.070 |
Why?
| | Biomarkers | 3 | 2021 | 4329 | 0.070 |
Why?
| | Prognosis | 3 | 2022 | 4331 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2010 | 8351 | 0.070 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 75 | 0.070 |
Why?
| | Uncertainty | 1 | 2009 | 145 | 0.070 |
Why?
| | Cells, Cultured | 7 | 2017 | 4112 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2008 | 86 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2006 | 3633 | 0.070 |
Why?
| | Gerbillinae | 3 | 2017 | 73 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 557 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 456 | 0.070 |
Why?
| | Atrophy | 2 | 2001 | 199 | 0.060 |
Why?
| | Conditioning, Classical | 1 | 2008 | 120 | 0.060 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 12 | 0.060 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 30 | 0.060 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.060 |
Why?
| | Jejunum | 1 | 2007 | 36 | 0.060 |
Why?
| | Periodicity | 1 | 2007 | 57 | 0.060 |
Why?
| | Games, Experimental | 1 | 2007 | 12 | 0.060 |
Why?
| | Soccer | 1 | 2007 | 40 | 0.060 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.060 |
Why?
| | Glutens | 1 | 2007 | 57 | 0.060 |
Why?
| | Qualitative Research | 2 | 2025 | 1720 | 0.060 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 146 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 395 | 0.060 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 207 | 0.060 |
Why?
| | Football | 1 | 2007 | 90 | 0.060 |
Why?
| | Fibroblasts | 1 | 2011 | 1033 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 505 | 0.060 |
Why?
| | Bumetanide | 1 | 2005 | 5 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 727 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1709 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 247 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 17 | 0.060 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.060 |
Why?
| | Diuretics | 1 | 2005 | 66 | 0.060 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 44 | 0.060 |
Why?
| | Auditory Pathways | 1 | 2005 | 53 | 0.050 |
Why?
| | Language | 1 | 2008 | 313 | 0.050 |
Why?
| | Fear | 1 | 2008 | 371 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 512 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 423 | 0.050 |
Why?
| | Pilot Projects | 2 | 2012 | 1878 | 0.050 |
Why?
| | Microcephaly | 1 | 2025 | 105 | 0.050 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 71 | 0.050 |
Why?
| | Ion Channel Gating | 1 | 2005 | 94 | 0.050 |
Why?
| | Length of Stay | 1 | 2010 | 1342 | 0.050 |
Why?
| | Simplexvirus | 1 | 2004 | 80 | 0.050 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 45 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2018 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5875 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2024 | 190 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 124 | 0.050 |
Why?
| | Cannabidiol | 1 | 2026 | 142 | 0.050 |
Why?
| | Nerve Net | 1 | 2007 | 284 | 0.050 |
Why?
| | Sodium | 1 | 2005 | 196 | 0.050 |
Why?
| | Odorants | 1 | 2024 | 114 | 0.050 |
Why?
| | Brain Waves | 1 | 2024 | 45 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 27 | 0.050 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 34 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 115 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2004 | 102 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1073 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 782 | 0.050 |
Why?
| | Smell | 1 | 2024 | 129 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 210 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 165 | 0.050 |
Why?
| | Thirst | 1 | 2003 | 4 | 0.050 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 74 | 0.050 |
Why?
| | Dronabinol | 1 | 2026 | 250 | 0.050 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 10 | 0.050 |
Why?
| | Vigabatrin | 1 | 2023 | 19 | 0.050 |
Why?
| | Electric Conductivity | 2 | 2004 | 85 | 0.050 |
Why?
| | Third Ventricle | 1 | 2003 | 16 | 0.050 |
Why?
| | Protein Binding | 3 | 2016 | 2239 | 0.050 |
Why?
| | Factor Analysis, Statistical | 1 | 2024 | 295 | 0.050 |
Why?
| | Drinking | 1 | 2003 | 44 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 3121 | 0.050 |
Why?
| | Syndactyly | 1 | 2022 | 10 | 0.050 |
Why?
| | Aggression | 1 | 2004 | 170 | 0.050 |
Why?
| | Longevity | 1 | 2024 | 179 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2003 | 129 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2023 | 102 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1979 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 121 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 10 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 238 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 167 | 0.040 |
Why?
| | Mammals | 1 | 2023 | 287 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 46 | 0.040 |
Why?
| | Anthropometry | 1 | 2022 | 203 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 666 | 0.040 |
Why?
| | Comorbidity | 2 | 2022 | 1652 | 0.040 |
Why?
| | Artifacts | 1 | 2001 | 142 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2023 | 257 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 23 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 2000 | 23 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1754 | 0.040 |
Why?
| | RNA Interference | 2 | 2014 | 470 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2001 | 180 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 365 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 502 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 483 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 386 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 179 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 2004 | 2766 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2022 | 146 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 49 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 666 | 0.040 |
Why?
| | tau Proteins | 1 | 2020 | 111 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 85 | 0.040 |
Why?
| | Neurology | 1 | 2020 | 107 | 0.030 |
Why?
| | Cost of Illness | 1 | 2020 | 322 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2915 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3678 | 0.030 |
Why?
| | Chronic Disease | 1 | 2004 | 1824 | 0.030 |
Why?
| | Benzothiadiazines | 1 | 2017 | 2 | 0.030 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 251 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2021 | 926 | 0.030 |
Why?
| | Risk Factors | 3 | 2009 | 10840 | 0.030 |
Why?
| | Nifedipine | 1 | 2017 | 27 | 0.030 |
Why?
| | Family | 1 | 2022 | 680 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 555 | 0.030 |
Why?
| | Dipeptides | 1 | 2017 | 55 | 0.030 |
Why?
| | Walking | 1 | 2022 | 544 | 0.030 |
Why?
| | Quinoxalines | 1 | 2017 | 63 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2455 | 0.030 |
Why?
| | Language Tests | 2 | 2007 | 24 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 165 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1758 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 104 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 290 | 0.030 |
Why?
| | Awareness | 1 | 1997 | 113 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 325 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 434 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2005 | 1324 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 728 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 33 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 141 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 196 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 507 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 326 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 184 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 271 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2020 | 798 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 991 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.020 |
Why?
| | Ibotenic Acid | 1 | 1993 | 5 | 0.020 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 12 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2014 | 273 | 0.020 |
Why?
| | Heart Diseases | 1 | 1997 | 341 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 30 | 0.020 |
Why?
| | Neural Pathways | 2 | 2005 | 318 | 0.020 |
Why?
| | Point Mutation | 1 | 2014 | 232 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2013 | 26 | 0.020 |
Why?
| | Magnesium | 1 | 1993 | 155 | 0.020 |
Why?
| | Reading | 1 | 1994 | 132 | 0.020 |
Why?
| | Video Recording | 2 | 2005 | 218 | 0.020 |
Why?
| | Incidence | 2 | 2010 | 2910 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2014 | 758 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 407 | 0.020 |
Why?
| | Cerebral Infarction | 2 | 1989 | 46 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 899 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2012 | 88 | 0.020 |
Why?
| | Cerebellum | 1 | 1994 | 225 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.020 |
Why?
| | Transfection | 2 | 2009 | 914 | 0.020 |
Why?
| | Memory, Episodic | 1 | 2012 | 57 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 630 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 276 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 208 | 0.020 |
Why?
| | Aging | 2 | 2021 | 1983 | 0.020 |
Why?
| | Levodopa | 1 | 1991 | 40 | 0.020 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 66 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 485 | 0.020 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2131 | 0.020 |
Why?
| | Ginkgo biloba | 1 | 2010 | 10 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2003 | 2962 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 3 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1030 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 92 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2010 | 75 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 107 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 409 | 0.020 |
Why?
| | Population Dynamics | 1 | 2010 | 142 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 295 | 0.020 |
Why?
| | Long-Term Care | 1 | 2010 | 116 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 66 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 105 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 530 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 70 | 0.020 |
Why?
| | Austria | 1 | 2008 | 8 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 188 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 45 | 0.020 |
Why?
| | Probability | 1 | 2009 | 308 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 277 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 84 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 162 | 0.020 |
Why?
| | Antipsychotic Agents | 1 | 2010 | 178 | 0.020 |
Why?
| | Plant Extracts | 1 | 2010 | 191 | 0.020 |
Why?
| | Germany | 1 | 2008 | 139 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 525 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 427 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 12 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 34 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 103 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 125 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 830 | 0.020 |
Why?
| | Life Style | 1 | 2010 | 495 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 834 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1034 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 540 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 413 | 0.010 |
Why?
| | Electromyography | 1 | 2008 | 417 | 0.010 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.010 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.010 |
Why?
| | Phenobarbital | 1 | 2005 | 22 | 0.010 |
Why?
| | United States | 1 | 2023 | 16041 | 0.010 |
Why?
| | Amino Acids | 1 | 2010 | 513 | 0.010 |
Why?
| | Electric Capacitance | 1 | 2005 | 5 | 0.010 |
Why?
| | Turtles | 1 | 2005 | 14 | 0.010 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 6 | 0.010 |
Why?
| | Sclerosis | 1 | 2005 | 11 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2005 | 37 | 0.010 |
Why?
| | Medication Adherence | 1 | 2010 | 535 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 126 | 0.010 |
Why?
| | Videotape Recording | 1 | 2005 | 36 | 0.010 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 40 | 0.010 |
Why?
| | Cadmium | 1 | 2005 | 68 | 0.010 |
Why?
| | Head Movements | 1 | 2005 | 38 | 0.010 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 150 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2005 | 60 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2005 | 88 | 0.010 |
Why?
| | Neural Conduction | 1 | 2005 | 92 | 0.010 |
Why?
| | Rotation | 1 | 2005 | 122 | 0.010 |
Why?
| | Chelating Agents | 1 | 2005 | 75 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2005 | 150 | 0.010 |
Why?
| | Reference Values | 2 | 1999 | 787 | 0.010 |
Why?
| | Acyclovir | 1 | 2004 | 97 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2497 | 0.010 |
Why?
| | Posture | 1 | 2005 | 180 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 403 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 131 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1728 | 0.010 |
Why?
| | Attention | 1 | 2007 | 459 | 0.010 |
Why?
| | Fever | 1 | 2004 | 320 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 65 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 340 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 511 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 1014 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1761 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Water | 1 | 2003 | 451 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2852 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4588 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 449 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 24 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 185 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 73 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1553 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1361 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1102 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 19 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 660 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 55 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 127 | 0.000 |
Why?
| | Frontal Lobe | 1 | 1991 | 159 | 0.000 |
Why?
| | Kidney | 1 | 1996 | 1491 | 0.000 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 56 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1270 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|